CHILDS JOHN W 4

What Happened
John W. Childs, a member of Veradermics' board of directors, acquired 294,117 shares in a private/open-market purchase on February 5, 2026 at $17.00 per share for a total of $4,999,989. On the same day, three series of the company's convertible preferred stock automatically converted into common stock immediately prior to the closing of the company’s initial public offering: Series A, B and C converted on a 10.067-for-1 basis, resulting in the issuance of 480,269, 906,862 and 520,758 common shares respectively (totaling 1,907,889 common shares). In addition, on February 3, 2026 Childs was reported as having been granted 51,525 derivative shares (an award/option) with an exercise/vesting profile noted in the filing.

Key Details

• Transaction dates: Feb 3, 2026 (award grant of 51,525 derivative shares); Feb 5, 2026 (open-market/private purchase and automatic conversions).
• Purchase: 294,117 shares at $17.00 each = $4,999,989 total.
• Automatic conversions: Series A → 480,269 shares; Series B → 906,862 shares; Series C → 520,758 shares (all converted on a 10.067-for-1 basis with no additional consideration).
• Grant: 51,525 derivative shares reported at $0.00; filing notes this option/award will be fully vested and exercisable on Feb 3, 2027.
• Shares owned after transaction: not specified in the filing.
• Ownership/beneficial notes: Some shares are held by J.W. Childs Associates (FL), L.P., which is owned by the John W. Childs 2013 Revocable Trust; as trustee Childs may be deemed to hold voting/dispositive power over those holdings.

Context

• The conversion entries reflect automatic conversions of preferred stock into common stock immediately prior to the IPO, not a cash transaction — the filing lists the preferred as disposed and common as acquired as part of that process.
• The $5.0M open-market/private purchase is a direct purchase by/for the insider and is typically seen as a more informative (bullish) signal than routine sales, though filings do not state motivation.
• The awarded 51,525 derivative shares are subject to vesting/exercise rules (fully exercisable one year after vesting commencement per the filing).

All items are reported facts from the Form 4 (Accession 0001628280-26-005906). This summary is informational and does not imply investment advice.